Available now: Building an Investable IP Portfolio Whitepaper
​

Rare diseases - are there sufficient incentives to develop treatments?

No items found.
​
January 1, 1970
#
Life
Table of contents
  • Toc Heading
  • Toc Heading

To mark Rare Disease Day 2012, Darren Smyth's latest IPKat post has a topical theme.

Darren highlights the pharmaceutical industry's reluctance to develop treatments for rare diseases where there is little prospect of financial gain, and wonders whether the patent system itself could provide incentives in these cases.

Recent Case Reports

See all Case Reports

Orders to Produce Evidence at the UPC
19 August 2026
GC Aesthetics, Avient, IQIP and Dall Energy: four 2026 UPC rulings reveal how courts weigh proportionality, confidentiality and timing before ordering a party to produce evidence under Rule 190.
​
Replacement parts and the value of asserting a narrower claim combination
17 July 2026
The UPC's Düsseldorf Local Division found that Wessper's cartridges indirectly infringed Brita's patent, and that a narrower claim combination can turn a consumable into an essential element.
​
Late Applications for Provisional Measures Refused for Lack of Urgency
14 July 2026
In Ericsson v ASUSTeK, the Milan Local Division refused a provisional measures application filed 21 months into the case, finding continuing infringement and rising losses alone do not establish urgency.
​